Prosecution Insights
Prosecution Insights
4 pending office actions • 4 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready
Based on the USPTO statutory response window for each pending office action. 4 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 4 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 4 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MARTIN, PAUL C | 1 | 42.0% | +21.7% |
| SALMON, KATHERINE D | 1 | 42.6% | +38.0% |
| SIMMONS, CHRIS E | 1 | 34.6% | +19.5% |
| PEEBLES, KATHERINE | 1 | 36.3% | +49.7% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17797450 | THERAPEUTIC COMBINATION FOR THE TREATMENT OF BRAIN ISCHEMIA AND SAID THERAPEUTIC COMBINATION FOR USE IN THE TREATMENT OF BRAIN ISCHEMIA | PEEBLES, KATHERINE | 189d overdue |
| 17797448 | USE OF A SOLUBLE GUANYLATE CYCLASE (sGC) STIMULATOR OR OF A COMBINATION OF A sGC STIMULATOR AND AN sGC ACTIVATOR FOR CONDITIONS WHEREIN THE HEME GROUP OF sGC IS OXIDIZED OR WHEREIN sGC IS DEFICIENT IN HEME | SIMMONS, CHRIS E | 22d overdue |
| 18029391 | 3D STRUCTURES FOR CELL GROWTH | MARTIN, PAUL C | 8d overdue |
| 18013178 | METHOD FOR DETECTING COLORECTAL CANCER | SALMON, KATHERINE D | 6d |
| Art Unit | Apps |
|---|---|
| 1653 | 1 |
| 1682 | 1 |
| 1622 | 1 |
| 1617 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18029391 | 3D STRUCTURES FOR CELL GROWTH | MARTIN, PAUL C | 1653 | §103 | Non-Final OA | 8d overdue | Pending | Mar 30, 2023 |
| 18013178 | METHOD FOR DETECTING COLORECTAL CANCER | SALMON, KATHERINE D | 1682 | §103 | Non-Final OA | 6d | Pending | Dec 27, 2022 |
| 17797448 | USE OF A SOLUBLE GUANYLATE CYCLASE (sGC) STIMULATOR OR OF A COMBINATION OF A sGC STIMULATOR AND AN sGC ACTIVATOR FOR CONDITIONS WHEREIN THE HEME GROUP OF sGC IS OXIDIZED OR WHEREIN sGC IS DEFICIENT IN HEME | SIMMONS, CHRIS E | 1622 | §103 | Non-Final OA | 22d overdue | Pending | Aug 04, 2022 |
| 17797450 | THERAPEUTIC COMBINATION FOR THE TREATMENT OF BRAIN ISCHEMIA AND SAID THERAPEUTIC COMBINATION FOR USE IN THE TREATMENT OF BRAIN ISCHEMIA | PEEBLES, KATHERINE | 1617 | §103 | Non-Final OA | 189d overdue | Pending | Aug 04, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial